Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

13.6%

3 terminated/withdrawn out of 22 trials

Success Rate

82.4%

-4.2% vs industry average

Late-Stage Pipeline

23%

5 trials in Phase 3/4

Results Transparency

79%

11 of 14 completed trials have results

Key Signals

3 recruiting11 with results

Enrollment Performance

Analytics

Phase 2
15(68.2%)
Phase 3
5(22.7%)
Phase 1
2(9.1%)
22Total
Phase 2(15)
Phase 3(5)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT07410455Phase 2Not Yet Recruiting

An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome

Role: lead

NCT06643260Phase 3Not Yet Recruiting

A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy

Role: lead

NCT05201404Phase 3Recruiting

Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

Role: lead

NCT06387342Phase 2Recruiting

Namodenoson Treatment of Advanced Pancreatic Cancer

Role: lead

NCT04697810Phase 2Recruiting

Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Role: lead

NCT00280917Phase 2Completed

Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

Role: lead

NCT00428974Phase 2Completed

Safety and Efficacy Study of CF101 to Treat Psoriasis

Role: lead

NCT02128958Phase 2Completed

Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)

Role: lead

NCT01235234Phase 3Completed

Trial of CF101 to Treat Patients With Dry Eye Disease

Role: lead

NCT03168256Phase 3Completed

CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis

Role: lead

NCT01034306Phase 2Completed

Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis

Role: lead

NCT00790218Phase 1Completed

A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma

Role: lead

NCT01033422Phase 2Completed

Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure

Role: lead

NCT00349466Phase 2Completed

Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca

Role: lead

NCT04333472Phase 2Completed

Piclidenoson for Treatment of COVID-19

Role: lead

NCT02647762Phase 3Terminated

CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis

Role: lead

NCT01265667Phase 2Completed

Trial of CF101 to Treat Patients With Psoriasis

Role: lead

NCT02927314Phase 2Completed

A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease

Role: lead

NCT00556894Phase 2Completed

Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients

Role: lead

NCT00837291Phase 2Withdrawn

A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee

Role: lead